RudaCure, a company specializing in the development of treatments for 感觉障碍, drew significant attention at a major international rheumatology conference.
According to RudaCure Inc. (CEO Yongho Kim), the company presented 临床前 疗效 results of its 骨关节炎 treatment candidate under development at the 美国风湿病学会 (ACR) Annual Meeting, held in 圣迪亚哥, USA from the 10th to the 15th, receiving considerable interest from attendees.
The compound discovered by RudaCure features a mechanism that selectively inhibits TRPV1 activation. In prior studies, it demonstrated TRPV1 inhibitory effects and reduced pain in 慢性疼痛 动物模型. Notably, unlike existing TRPV1 antagonists, it did not cause 异常发热.
In addition to the 壁报发表, RudaCure was also invited to the BCRC (Basic & Clinical Research Conference) session—one of the key programs at ACR 2023—where the company's cumulative research findings were presented directly to the audience.
RudaCure CEO Yongho Kim stated, "By moving away from traditional 药物开发 methods with low success rates in the pain field and leveraging computational science, we were able to rapidly identify 先导化合物s," adding, "In particular, having a diverse range of pain models allowed us to quickly and accurately address 药物开发 and 副作用 challenges, which is a key advantage."
He further noted, "Based on these research results, we plan to expand the indications for various pain conditions," and "We are also pursuing the development of a drug that can suppress pain for several months with a single administration through formulation research."
Source: Pharmnews (http://www.pharmnews.com)
http://www.biospectator.com/view/news_view.php?varAtcId=20336